Current recommendations and recent progress in endometrial cancer

Rákkutatás · Endometrial cancer

Pembrolizumab has been approved for patients with microsatellite‑instability (MSI‑high) metastatic endometrial cancer.

Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite‑instable, metastatic disease, anti‑programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.

Endometrial cancer incidence is increasing; pembrolizumab offers a targeted therapy for MSI‑high metastatic disease, potentially improving patient survival and reducing reliance on conventional chemotherapy.

Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Eredeti forrás

Kapcsolódó jelek